ARTICLE SUMMARY:
Teva Pharmaceutical Industries has always seen device innovation for the delivery of its drugs as a means of value-added differentiation and a competitive advantage. In 2015, Teva acquired a digital health company with expertise in developing software and product solutions to aid in compliance and adherence improvement in the management of respiratory diseases.
One thing has become patently obvious over the years: no matter how far therapies advance or how efficacious a drug or device therapy proves to be in a controlled clinical trial, in real life, success or failure is highly dependent upon factors relating to the individual patient.
